Cardinal Health (CAH) has been seeing mixed results in the market, with rounds of both underperformance and outperforming competitors. Despite certain losses and headwinds predicted for growth, the company reaffirmed its Fiscal 2024
non-GAAP EPS guidance and long-term targets. While underperformance, market dips, and losses such as the
nonrenewal of OptumRx customer contracts have impacted the stock, CAH has also shown its strength as a value stock for investors. Dividends have increased, with strong trading days creating favorable conditions. Cardinal Health continues to hold strong with its portfolio, justifying its retention. Recently, it hit a
52-week high, but it has forecasted lower profits for its medical unit. Fiscal 2024 results have so far surpassed analyst EPS forecasts, raising FY24 guidance, and robust revenue growth expected. The company is streamlining its operations and enhancing its workflow through acquisitions, like that of
Specialty Networks and its PPS Analytics platform, expanding its presence in specialty pharmaceuticals. However, some insider stock sales might indicate potential weaknesses down the line.
Cardinal Health CAH News Analytics from Fri, 03 Nov 2023 07:00:00 GMT to Sun, 04 Aug 2024 14:16:34 GMT -
Rating 5
- Innovation 0
- Information 7
- Rumor 1
